REFERENCES
1. Ostrom QT, Price M, Neff C, et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the united states in 2016-2020. Neuro Oncol 2023;25:iv1-99.
2. Stupp R, Mason WP, van den Bent MJ, et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005;352:987-96.
3. Villani V, Prosperini L, Lecce M, et al. Recurrent glioblastoma: which treatment? A real-world study from the neuro-oncology unit “Regina Elena” national cancer institute. Neurol Sci 2022;43:5533-41.
4. She L, Gong X, Su L, Liu C. Effectiveness and safety of tumor-treating fields therapy for glioblastoma: a single-center study in a Chinese cohort. Front Neurol 2022;13:1042888.
5. Mehta M, Wen P, Nishikawa R, Reardon D, Peters K. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Crit Rev Oncol Hematol 2017;111:60-5.
6. Karachi A, Dastmalchi F, Mitchell DA, Rahman M. Temozolomide for immunomodulation in the treatment of glioblastoma. Neuro Oncol 2018;20:1566-72.
7. He Q, Li L, Ren Q. The prognostic value of preoperative systemic inflammatory response index (SIRI) in patients with high-grade glioma and the establishment of a nomogram. Front Oncol 2021;11:671811.
8. Strik HM, Marosi C, Kaina B, Neyns B. Temozolomide dosing regimens for glioma patients. Curr Neurol Neurosci Rep 2012;12:286-93.
9. Balana C, Vaz MA, Manuel Sepúlveda J, et al. A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01). Neuro Oncol 2020;22:1851-61.
10. Gately L, Mesía C, Sepúlveda JM, et al. A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma. J Neurooncol 2024;166:407-15.
11. Blumenthal DT, Gorlia T, Gilbert MR, et al. Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. Neuro Oncol 2017;19:1119-26.
12. Darlix A, Baumann C, Lorgis V, et al. Prolonged administration of adjuvant temozolomide improves survival in adult patients with glioblastoma. Anticancer Res 2013;33:3467-74.
13. Barbagallo GM, Paratore S, Caltabiano R, et al. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Neurosurg Focus 2014;37:E4.
14. Abete-Fornara G, Bintintan Socaciu P, Fanizzi C, Fiore G, Locatelli M, Caroli M. Neuropsychological functioning during chemotherapy with temozolomide in high-grade glioma patients: a retrospective single centre study. J Neurooncol 2023;165:561-8.
15. Gupta T, Selvarajan JMP, Kannan S, Menon N, Dasgupta A, Chatterjee A. Updated systematic review and meta-analysis of extended adjuvant temozolomide in patients with newly diagnosed glioblastoma. Neurooncol Adv 2023;5:vdad086.
16. Chen J, Wang T, Liu W, et al. Extended adjuvant temozolomide in newly diagnosed glioblastoma: a single-center retrospective study. Front Oncol 2022;12:1000501.
17. Gilbert MR, Wang M, Aldape KD, et al. Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013;31:4085-91.
18. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005;352:997-1003.
19. Sareen H, Ma Y, Becker TM, Roberts TL, de Souza P, Powter B. Molecular biomarkers in glioblastoma: a systematic review and meta-analysis. Int J Mol Sci 2022;23:8835.
20. Di Carlo DT, Cagnazzo F, Benedetto N, Morganti R, Perrini P. Multiple high-grade gliomas: epidemiology, management, and outcome. A systematic review and meta-analysis. Neurosurg Rev 2019;42:263-75.
21. Haque W, Thong Y, Verma V, Rostomily R, Brian Butler E, Teh BS. Patterns of management and outcomes of unifocal versus multifocal glioblastoma. J Clin Neurosci 2020;74:155-9.
22. Habiboglu R, Kayali I, Saricanbaz I, Tezcan Y. Comparative analysis of IDH wild-type multifocal and unifocal glioblastomas: prognostic factors and survival outcomes in focus. Turk Neurosurg 2023;33:1126-31.
23. Li F, Zhang Y, Wang N, et al. Evaluation of the prognosis of neuroglioma based on dynamic magnetic resonance enhancement. World Neurosurg 2020;138:663-71.
